Spine BioPharma's Impressive Clinical Trial Milestone
Spine BioPharma, Inc. has made noteworthy strides in developing non-opiate, non-surgical treatments for Degenerative Disc Disease (DDD). The company has announced the successful completion of patient enrollment in its U.S. Phase 3 clinical trial for SB-01 For Injection (SB-01). This achievement is a significant step forward in tackling chronic low back pain (CLBP), a condition that impacts millions of people.
Exploring the MODEL Trial
The Phase 3 MODEL trial—short for Moderate-Severe Degenerative Disc Disease Evaluation of the Lumbar Spine—enrolled 417 patients from 30 investigational sites across the U.S. over two years. What makes this trial special is that SB-01 is the first intradiscal pharmacologic treatment to reach Phase 3 studies specifically aimed at chronic low back pain and its related functional impairments caused by DDD.
Leadership Insights
Marc Viscogliosi, CEO of Spine BioPharma, highlighted the importance of this achievement for patient care. He stated, “This is an important milestone for the patient and physician community, and for the Company. After years of conservative treatment, DDD patients often face the difficult choice of surgery, which can be costly and comes with unpredictable outcomes.” He expressed satisfaction with the timely completion of enrollment, emphasizing that it brings SB-01 closer to addressing the unmet needs faced by millions.
Acknowledgments
Fran Magee, DVM, Chief Technology Officer, acknowledged the collaborative effort involved in this trial. “We would like to thank the patients, clinical trial site staff and physicians, and our vendor partners for their participation in this landmark trial. The insights garnered from the collected data may illuminate treatment challenges and present a potential new therapeutic option for DDD patients.”
Understanding Degenerative Disc Disease
Degenerative Disc Disease is a common condition affecting around 266 million people worldwide, with approximately 22.5 million Americans diagnosed annually. Treating this condition is often difficult, as current options mainly involve managing symptoms through physical therapy, NSAIDs, chiropractic care, or opioids. In more severe, chronic cases, interventions like epidural steroid injections, radiofrequency ablation, and surgical procedures are sometimes considered, but these come with varying effectiveness and significant risks.
Key Aspects of the MODEL Clinical Trial
The SB-01 MODEL trial is a critical multi-center study that is randomized, double-blind, and placebo-controlled. Its aim is to assess both the safety and efficacy of SB-01 For Injection in adult patients suffering from chronic low back pain and related impairments due to lumbar DDD.
A Closer Look at SB-01 For Injection
SB-01 comprises a synthetic peptide with seven amino acids, designed to interact with and regulate TGF-Beta activity. TGF-Beta is an essential cytokine that plays a key role in various cellular functions; when its regulation goes awry, it can lead to inflammation and heightened nerve sensitivity. The goal with SB-01 is to restore the balance of TGF-Beta levels, reducing adverse effects while maintaining its beneficial functions.
About Spine BioPharma
Spine BioPharma is dedicated to developing innovative, non-opiate, non-surgical treatments aimed at alleviating pain, restoring functionality, and slowing or halting disease progression. Their flagship candidate, SB-01 For Injection, holds promise as a groundbreaking treatment for DDD, potentially offering significant clinical benefits for pain relief, functional restoration, and overall disease management.
Frequently Asked Questions
What is the primary aim of the SB-01 clinical trial?
The main focus is to assess the safety and effectiveness of SB-01 in treating chronic low back pain linked to Degenerative Disc Disease.
How many patients were part of the trial?
The trial involved 417 patients who were enrolled across 30 investigational sites in the U.S.
Why is it important that enrollment has been completed?
Completing enrollment is a critical milestone that advances the development of a potential new treatment for those suffering from chronic low back pain, addressing a significant medical need.
How does SB-01 differ from traditional therapies?
Unlike traditional therapies that generally focus on managing symptoms, SB-01 takes a targeted pharmacologic approach aimed at treating the underlying issues related to DDD.
What could the trial's success mean for patients?
If successful, the results could open up a new treatment option for millions dealing with chronic low back pain, improving patient care in this area.
